TechsoMed
- Industry
- Medical Imaging Software
- Founded Year
- 2012
- Headquarters
- 2 Meir Weisgal St, Rehovot, 7632605, Israel
- Employee Count
- 40
Key People
- Yossi Abu - Founder and CEO
- Bob Gerberich - CCO & Head of North America
- Eran Naveh - Chief Strategy Officer
- Tal Sitbon - Chief Operating Officer
- Yogev Zohar - Vice President of Products
- Talia Goshen - Director, Contracts and Licensing
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and business development.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: TechsoMed addresses a significant gap in real-time monitoring for thermal ablation procedures.
By providing real-time visualization of tissue viability, TechsoMed's technology has the potential to significantly reduce failure rates in thermal ablation procedures.
- Competition
-
Aspect: First mover
Summary: TechsoMed appears to be a pioneer in real-time monitoring for thermal ablation using ultrasound imaging.
While pioneering technology offers a competitive edge, it also involves risks related to market education and acceptance.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing real-time tissue viability imaging using standard ultrasound is highly complex.
The integration of AI and real-time imaging algorithms into standard ultrasound devices requires significant technical innovation and validation.
- Patent
-
Aspect: Very Strong
Summary: TechsoMed holds patents in the 'Medical Or Veterinary Science; Hygiene' category.
Holding patents in relevant categories can protect the company's innovations and provide leverage in the market.
- Financing
-
Aspect: Well-funded
Summary: TechsoMed has raised $9.6M over two funding rounds.
The funds raised enable the company to advance its technology and pursue regulatory approvals necessary for commercialization.
- Regulatory
-
Aspect: Running FIH
Summary: TechsoMed is collaborating with medical centers to secure regulatory approval for its BioTrace system.
Engaging in clinical collaborations and pursuing regulatory approvals are essential steps toward bringing the technology to market.
Opportunity Rollup
- Odds of Success
- 3.2
- Peak Market Share
- 3.65
- Segment CAGR
- 2.9%
- Market Segment
- Medical Imaging Software
- Market Sub Segment
- Real-time Monitoring for Thermal Ablation
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.18 |
| 2 | 0.55 |
| 3 | 1.28 |
| 4 | 2.55 |
| 5 | 3.65 |
Key Takeaway
TechsoMed's innovative real-time monitoring technology addresses a critical need in thermal ablation procedures, supported by a strong team and adequate funding, positioning it well for market entry and growth.